title: Vascular disease in the antiphospholipid syndrome: a comparison with the patient population with atherosclerosis.
abstract: The antiphospholipid syndrome was diagnosed in 19 of 1078 patients treated between 1987 and 1991. All patients with antiphospholipid syndrome had either anticardiolipin antibody (16/19) or lupus anticoagulant (10/19); three patients had thrombocytopenia, eight patients had a prolonged partial thromboplastin time, and 10 patients had an elevated erythrocyte sedimentation rate. The most common site of involvement was the cerebral circulation (nine patients), manifested by transient ischemic attacks or stroke. Eight patients had upper extremity disease, characterized by symptoms of Raynaud's phenomenon, with angiographic lesions involving the brachial, radial, ulnar, and/or digital arteries. Lower extremity disease occurred in seven patients, with clinical presentations similar to those of atherosclerosis and varying angiographic patterns. In comparison with the population having atherosclerosis, patients with arterial manifestations of antiphospholipid syndrome were more likely to be women (13 of 19 versus 411 of 1078, p less than 0.02), were significantly younger (46.2 years versus 63.6 years, p less than 0.0001), did not smoke (1 of 19 patients versus 700 of 1078, p less than 0.0001), had a higher percentage of upper extremity involvement (8 of 18 versus 13 of 1078, p less than 0.0001), and had a higher incidence of early graft failure (9 of 12 grafts versus 13 of 371 grafts, p less than 0.0001). The syndrome is associated with the repetitive failure of vascular reconstructions and occlusion of native vessels. Antiphospholipid syndrome should therefore be suspected in young, female, nonsmokers with vascular disease, especially those with involvement of the upper extremity, cerebrovascular disease with normal findings on extracranial carotid angiography, and premature graft failure.
authors.affiliation: Department of Surgery, University of Rochester School of Medicine and Dentistry, NY.
authors.forename: C K
authors.initials: CK
authors.lastname: Shortell
authors.forename: K
authors.initials: K
authors.lastname: Ouriel
authors.forename: R M
authors.initials: RM
authors.lastname: Green
authors.forename: J J
authors.initials: JJ
authors.lastname: Condemi
authors.forename: J A
authors.initials: JA
authors.lastname: DeWeese
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D015901:Angiography, Digital Subtraction; D016736:Antiphospholipid Syndrome / Q000097:blood / Q000150:complications*; D001157:Arterial Occlusive Diseases / Q000000981:diagnostic imaging / Q000209:etiology* / Q000601:surgery; D001161:Arteriosclerosis / Q000097:blood / Q000150:complications*; D001323:Autoantibodies / Q000097:blood; D002308:Cardiolipins / Q000276:immunology; D005260:Female; D006083:Graft Occlusion, Vascular / Q000209:etiology; D006801:Humans; D016682:Lupus Coagulation Inhibitor / Q000097:blood; D008297:Male; D008875:Middle Aged; D012737:Sex Factors
chemical_list: D001323:Autoantibodies; D002308:Cardiolipins; D016682:Lupus Coagulation Inhibitor